Matthew R. Smith

Denosumab versus zoledronic acid for treatment of bone metastases in men with castration-resistant prostate cancer: a randomised, double-blind study

Karim Fizazi, Michael A. Carducci, Matthew R. Smith et al. · The Lancet · 2011 · 2K citations · Full text

Medicine, Oncology, Urology +17

Eligibility and Response Guidelines for Phase II Clinical Trials in Androgen-Independent Prostate Cancer: Recommendations From the Prostate-Specific Antigen Working Group

Glenn J. Bubley, Michael A. Carducci, William L. Dahut et al. · Journal of Clinical Oncology · 1999 · 984 citations

Medicine, Oncology, Genitourinary Oncology +16

Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer

Karim Fizazi, Neal D. Shore, Teuvo L.J. Tammela et al. · New England Journal of Medicine · 2019 · 922 citations · Full text

Medicine, Oncology, Pharmacology +15

Denosumab and bone-metastasis-free survival in men with castration-resistant prostate cancer: results of a phase 3, randomised, placebo-controlled trial

Matthew R. Smith, Fred Saad, Robert E. Coleman et al. · The Lancet · 2011 · 797 citations · Full text

Medicine, Oncology, Urology +17

Changes in Body Composition during Androgen Deprivation Therapy for Prostate Cancer

Matthew R. Smith, Joel S. Finkelstein, Francis J. McGovern et al. · The Journal of Clinical Endocrinology & Metabolism · 2002 · 669 citations · Full text

Medicine, Oncology, Urology +17